AI-CVD vs ElucidVivo A.3
AI Verdict
Choose AI-CVD if…
Choose AI-CVD if your primary goal is opportunistic, broad-spectrum screening for various cardiovascular and multisystem diseases using existing CT scans. This tool is ideal for identifying hidden health risks and performing early detection without requiring additional imaging, radiation, or workflow disruption, leveraging data already collected for other purposes.
View AI-CVD →Choose ElucidVivo A.3 if…
Choose ElucidVivo A.3 if you require detailed, quantitative analysis of arterial plaque composition and stability from CT angiography to stratify atherosclerosis patients and optimize treatment decisions. This tool excels at providing granular insights into plaque characteristics, including LRNC and calcifications, validated against histology, to guide targeted interventions.
View ElucidVivo A.3 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AI-CVD | ElucidVivo A.3 |
|---|---|---|
| Deployment | Unknown | Cloud and on-premise secure deployment. |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AI-CVDAI-CVD emphasizes 'no additional imaging, radiation, contrast, or workflow disruption' and performs 'opportunistic screening' using existing CT scans, suggesting a seamless and passive integration into current clinical workflows. This approach minimizes user effort and changes to established practices, making it highly usable for broad application. ElucidVivo A.3, while offering powerful visualizations, likely requires more active user engagement for its detailed plaque analysis.
Clinical Value
ElucidVivo A.3Both tools are FDA-cleared and offer significant clinical value. However, ElucidVivo A.3 provides highly specialized, histology-validated quantitative analysis of arterial plaque composition and stability, including the derivation of fractional flow reserve (FFRct). This deep, precise characterization directly aids in advanced atherosclerosis patient stratification and optimizes treatment decisions, offering a more targeted and impactful clinical utility for diagnosed atherosclerosis.
Pricing & Value
ElucidVivo A.3While both require contacting the vendor for pricing, ElucidVivo A.3 offers more transparency by stating its pricing options include annual software licensing or subscription-based access, tailored to cath lab volume and hospital needs. Furthermore, it has secured CPT codes and broad CMS reimbursement for its quantitative coronary plaque analysis, indicating a clearer path to financial value and adoption for healthcare providers.
Enterprise Readiness
AI-CVDBoth tools are FDA-cleared and designed for clinical integration. AI-CVD explicitly states 'Cloud' deployment, which typically offers greater scalability, easier maintenance, and simplified integration for large enterprise healthcare systems. ElucidVivo A.3 mentions integration with PACS/EMR, which is crucial, but its deployment is described as 'likely on-premise or cloud-based,' making Tool A's cloud-native approach a more definitive advantage for enterprise readiness.
Innovation
ElucidVivo A.3Both are innovative, but ElucidVivo A.3's 'CT Virtual Histologyu2122' and its ability to objectively quantify specific plaque components like Lipid-Rich Necrotic Core (LRNC) and derive FFRct, validated against ground-truth histology, represent a more advanced and novel application of AI for precision diagnostics and treatment planning in atherosclerosis. This level of detailed, non-invasive plaque characterization pushes the boundaries of personalized cardiovascular medicine. AI-CVD's opportunistic screening is innovative for broad detection but less specialized.
Support & Docs
TieNeither the provided structured facts nor the web search results offer explicit information regarding customer support channels, service level agreements, or publicly available documentation for either AI-CVD or ElucidVivo A.3. Without this information, it is not possible to distinguish between the two tools on this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AI-CVD | ElucidVivo A.3 |
|---|---|---|
| Name | AI-CVD | ElucidVivo A.3 |
| Company | HeartLung Corporation | Elucid Bioimaging |
| Key Functionality | Opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, enabling early detection of hidden health risks. | Quantitative analysis of arterial plaque composition and stability from CT angiography to assist in atherosclerosis patient stratification and optimize treatment decisions. |
| Specialties | Cardiology, Pulmonology, Radiology | Cardiology, Radiology, Vascular Surgery |
| Specific Measurements/Analysis (Examples) | Coronary Artery Calcium (CAC) scoring, Aortic wall, aortic valve, and mitral valve calcium analysis, Cardiac chamber volumetry, Epicardial fat volumetry, Aorta and pulmonary artery sizing | Quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images, Derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity |
Videos
Demos, reviews, and walkthroughs featuring AI-CVD and ElucidVivo A.3.